Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 13, 2009 - Issue 9
Submit an article Journal homepage
62
Views
7
CrossRef citations to date
0
Altmetric
Reviews

Matrix metalloproteinases in the pathophysiology and progression of gynecological malignancies: could their inhibition be an effective therapeutic approach?

Vassilios Memtsas National & Kapodistrian University of Athens, Medical School, Department of Forensic Medicine & Toxicology, 75 Mikras Asias street, GR-11527, Athens, Greece +30 210 7462413; +30 210 7716098; [email protected]
,
Apostolos Zarros National & Kapodistrian University of Athens, Medical School, Department of Forensic Medicine & Toxicology, 75 Mikras Asias street, GR-11527, Athens, Greece +30 210 7462413; +30 210 7716098; [email protected]
&
Stamatios Theocharis National & Kapodistrian University of Athens, Medical School, Department of Forensic Medicine & Toxicology, 75 Mikras Asias street, GR-11527, Athens, Greece +30 210 7462413; +30 210 7716098; [email protected]
Pages 1105-1120 | Published online: 15 Jul 2009

Bibliography

  • Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516
  • Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2(3):161-74
  • Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991;51(18 Suppl):5054s-9s
  • Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89(17):1260-70
  • Kinoh H, Sato H, Tsunezuka Y, et al. MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci 1996;109(Pt 5):953-9
  • Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270(10):5331-8
  • Knauper V, Will H, Lopez-Otin C, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996;271(29):17124-31
  • Parsons SL, Watson SA, Brown PD, et al. Matrix metalloproteinases. Br J Surg 1997;84(2):160-6
  • Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189(3):300-8
  • Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274(31):21491-4
  • Ohuchi E, Imai K, Fujii Y, et al. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997;272(4):2446-51
  • Pei D. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem 1999;274(13):8925-32
  • Sato H, Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem 1996;119(2):209-15
  • Tunuguntla R, Ripley D, Sang QX, et al. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 2003;89(3):453-9
  • Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998;10(5):602-8
  • Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2(9):657-72
  • Docherty AJ, Lyons A, Smith BJ, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985;318(6041):66-9
  • Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4(2):197-250
  • Greene J, Wang M, Liu YE, et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996;271(48):30375-80
  • Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 1995;270(24):14313-8. Erratum in: J Biol Chem 1996;271(5):2874
  • Kolkenbrock H, Hecker-Kia A, Orgel D, et al. Activation of progelatinase A and progelatinase A/TIMP-2 complex by membrane type 2-matrix metalloproteinase. Biol Chem 1997;378(2):71-6
  • Levi E, Fridman R, Miao HQ, et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996;93(14):7069-74
  • Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994;370(6490):555-7
  • Suzuki M, Raab G, Moses MA, et al. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 1997;272(50):31730-7
  • Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001;11(11):S37-43
  • Parks WC. Matrix metalloproteinases in repair. Wound Repair Regen 1999;7(6):423-32
  • Rodgers WH, Osteen KG, Matrisian LM, et al. Expression and localization of matrilysin, a matrix metalloproteinase, in human endometrium during the reproductive cycle. Am J Obstet Gynecol 1993;168(1 Pt 1):253-60
  • Rodgers WH, Matrisian LM, Giudice LC, et al. Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest 1994;94(3):946-53
  • Martelli M, Campana A, Bischof P. Secretion of matrix metalloproteinases by human endometrial cells in vitro. J Reprod Fertil 1993;98(1):67-76
  • Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992;14(7):455-63
  • Hampton AL, Salamonsen LA. Expression of messenger ribonucleic acid encoding matrix metalloproteinases and their tissue inhibitors is related to menstruation. J Endocrinol 1994;141(1):R1-3
  • Goffin F, Munaut C, Frankenne F, et al. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium. Biol Reprod 2003;69(3):976-84
  • Graesslin O, Cortez A, Fauvet R, et al. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical–pathological correlation study. Ann Oncol 2006;17(4):637-45
  • Pilka R, Norata GD, Domanski H, et al. Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer. Gynecol Oncol 2004;94(3):661-70
  • Pilka R, Whatling C, Domanski H, et al. Epithelial expression of matrix metalloproteinase-26 is elevated at mid-cycle in the human endometrium. Mol Hum Reprod 2003;9(5):271-7
  • Maatta M, Soini Y, Liakka A, et al. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation. Am J Clin Pathol 2000;114(3):402-11
  • Pilka R, Domanski H, Hansson S, et al. Endometrial TIMP-4 mRNA is high at midcycle and in hyperplasia, but down-regulated in malignant tumours. Coordinated expression with MMP-26. Mol Hum Reprod 2004;10(9):641-50
  • Chegini N, Rhoton-Vlasak A, Williams RS. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Fertil Steril 2003;80(3):564-70
  • Curry TE Jr, Smith MF. Impact of extracellular matrix remodeling on ovulation and the folliculo-luteal transition. Semin Reprod Med 2006;24(4):228-41
  • Ohnishi J, Ohnishi E, Shibuya H, Takahashi T. Functions for proteinases in the ovulatory process. Biochim Biophys Acta 2005;1751(1):95-109
  • Curry TE Jr, Osteen KG. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003;24(4):428-65
  • Curry TE Jr, Osteen KG. Cyclic changes in the matrix metalloproteinase system in the ovary and uterus. Biol Reprod 2001;64(5):1285-96
  • Winkler M, Rath W. Changes in the cervical extracellular matrix during pregnancy and parturition. J Perinat Med 1999;27(1):45-60
  • Becher N, Hein M, Uldbjerg N, Danielsen CC. Balance between matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) in the cervical mucus plug estimated by determination of free non-complexed TIMP. Reprod Biol Endocrinol 2008;6:45. Published online 30 September 2008, doi:10.1186/1477-7827-6-45
  • Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92(8):827-39
  • Lukes A, Mun-Bryce S, Lukes M, et al. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 1999;19(3):267-84
  • Rooprai HK, Rucklidge GJ, Panou C, et al. The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. Br J Cancer 2000;82(1):52-5
  • Torng PL, Mao TL, Chan WY, et al. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol 2004;92(2):559-67
  • Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000;6(12):4823-30
  • Huang HY, Wen Y, Irwin JC, et al. Cytokine-mediated regulation of 92-kilodalton type IV collagenase, tissue inhibitor or metalloproteinase-1 (TIMP-1), and TIMP-3 messenger ribonucleic acid expression in human endometrial stromal cells. J Clin Endocrinol Metab 1998;83(5):1721-9
  • Rawdanowicz TJ, Hampton AL, Nagase H, et al. Matrix metalloproteinase production by cultured human endometrial stromal cells: identification of interstitial collagenase, gelatinase-A, gelatinase-B, and stromelysin-1 and their differential regulation by interleukin-1 alpha and tumor necrosis factor-alpha. J Clin Endocrinol Metab 1994;79(2):530-6
  • Singer CF, Marbaix E, Kokorine I, et al. Paracrine stimulation of interstitial collagenase (MMP-1) in the human endometrium by interleukin 1α and its dual block by ovarian steroids. Proc Natl Acad Sci USA 1997;94(19):10341-5
  • Bruner KL, Rodgers WH, Gold LI, et al. Transforming growth factor β mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci USA 1995;92(16):7362-6
  • Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541-73
  • Monge M, Colas E, Doll A, et al. ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res 2007;67(14):6753-9
  • Iwasaka C, Tanaka K, Abe M, et al. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 1996;169(3):522-31
  • Higashino F, Yoshida K, Noumi T, et al. Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters. Oncogene 1995;10(7):1461-3
  • Wasylyk C, Gutman A, Nicholson R, et al. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 1991;10(5):1127-34
  • Nishikawa A, Iwasaki M, Akutagawa N, et al. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential. Gynecol Oncol 2000;79(2):256-63
  • Ueda M, Terai Y, Kumagai K, et al. Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. Gynecol Oncol 2001;82(1):162-6
  • Prifti S, Lelle I, Zhong G, et al. Matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression is not regulated by norgestimate or norelgestromin. Gynecol Endocrinol 2004;18(1):23-7
  • Salamonsen LA, Butt AR, Hammond FR, et al. Production of endometrial matrix metalloproteinases, but not their tissue inhibitors, is modulated by progesterone withdrawal in an in vitro model for menstruation. J Clin Endocrinol Metab 1997;82(5):1409-15
  • Irwin JC, Kirk D, Gwatkin RB, et al. Human endometrial matrix metalloproteinase-2, a putative menstrual proteinase. Hormonal regulation in cultured stromal cells and messenger RNA expression during the menstrual cycle. J Clin Invest 1996;97(2):438-47
  • Park DW, Ryu HS, Choi DS, et al. Localization of matrix metalloproteinases on endometrial cancer cell invasion in vitro. Gynecol Oncol 2001;82(3):442-9
  • Cioppi F, Simi L, Luciani P, et al. Expression of uteroglobin and matrix metalloproteinase-9 genes in endometrial cancer: relationship to estrogen and progesterone receptor status. Oncol Rep 2004;11(2):427-33
  • Mizumoto H, Saito T, Ashihara K, et al. Acceleration of invasive activity via matrix metalloproteinases by transfection of the estrogen receptor-α gene in endometrial carcinoma cells. Int J Cancer 2002;100(4):401-6
  • Saito T, Mizumoto H, Tanaka R, et al. Overexpressed progesterone receptor form B inhibit invasive activity suppressing matrix metalloproteinases in endometrial carcinoma cells. Cancer Lett 2004;209(2):237-43
  • Park YH, Ryu HS, Choi DS, et al. Effects of hepatocyte growth factor on the expression of matrix metalloproteinases and their tissue inhibitors during the endometrial cancer invasion in a three-dimensional coculture. Int J Gynecol Cancer 2003;13(1):53-60
  • Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996;85(5):683-9362
  • Zorio E, Gilabert-Estelles J, Espana F, et al. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 2008;15(9):923-9
  • Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986;55:1037-57
  • Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000;10(6):415-33
  • Mueller J, Brebeck B, Schmalfeldt B, et al. Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential. Virchows Arch 2000;437(6):618-24
  • Sillanpaa S, Anttila M, Suhonen K, et al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol 2007;28(5):280-9
  • Westerlund A, Apaja-Sarkkinen M, Hoyhtya M, et al. Gelatinase A-immunoreactive protein in ovarian lesions – prognostic value in epithelial ovarian cancer. Gynecol Oncol 1999;75(1):91-8
  • Garzetti GG, Ciavattini A, Lucarini G, et al. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res 1995;15(6B):2799-804
  • Taylor DD, Lyons KS, Gercel-Taylor C. Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol Oncol 2002;84(3):443-8
  • Kenny HA, Kaur S, Coussens LM, et al. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008;118(4):1367-79
  • Naylor MS, Stamp GW, Davies BD, et al. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 1994;58(1):50-6
  • Cowden Dahl KD, Symowicz J, Ning Y, et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells. Cancer Res 2008;68(12):4606-13
  • Wu X, Li H, Kang L, et al. Activated matrix metalloproteinase-2–a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 2002;84(1):126-34
  • Acar A, Onan A, Coskun U, et al. Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer. Med Oncol 2008;25(3):279-83
  • Adley BP, Gleason KJ, Yang XJ, et al. Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol Oncol 2009;112(2):319-24
  • Lewandowski KC, Komorowski J, O'Callaghan CJ, et al. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91(3):1173-7
  • Liu B, Cai LY, Lv HM, et al. Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1. Gynecol Endocrinol 2008;24(5):285-8
  • Davidson B, Goldberg I, Gotlieb WH, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17(10):799-808
  • Afzal S, Lalani EN, Poulsom R, et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol 1998;29(2):155-65
  • Brun JL, Cortez A, Commo F, et al. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol 2008;33(6):1239-46
  • Mitra A, Chakrabarti J, Chattopadhyay N, et al. Membrane-associated MMP-2 in human cervical cancer. J Environ Pathol Toxicol Oncol 2003;22(2):93-100
  • Yang EV, Sood AK, Chen M, et al. Norepinephrine up-regulates the expression of vascular endothelial factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006;66(21):10357-64
  • Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006;12(2):369-75
  • Ueda M, Terai Y, Yamashita Y, et al. Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int J Cancer 2002;98(3):335-43
  • Garzetti GG, Ciavattini A, Lucarini G, et al. Recurrence patterns in locally advanced cervical carcinoma: role of nodal status and 72-kDa metalloproteinase index. Gynecol Oncol 1996;61(1):83-9
  • Nasr M, Ayyad SB, El-Lamie IK, et al. Expression of matrix metalloproteinase-2 in preinvasive and invasive carcinoma of the uterine cervix. Eur J Gynaecol Oncol 2005;26(2):199-202
  • Asha Nair S, Karunagaran D, Nair MB, et al. Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol 2003;129(2):123-31
  • Gaiotto MA, Focchi J, Ribalta JL, et al. Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma. Am J Obstet Gynecol 2004;190(5):1278-82
  • Ahmed MI, Salahy EE, Tawfiq H, et al. Matrix metalloproteinase-2, squamous cell carcinoma antigen, and tissue polypeptide-specific antigen expression in Egyptian patients with cervical carcinoma: relationship with prognosis. Dis Markers 2004;20(6):333-43
  • Davidson B, Goldberg I, Kopolovic J, et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma–a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999;73(3):372-82
  • Di Nezza LA, Misajon A, Zhang J, et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 2002;94(5):1466-75
  • Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 2003;22(2-3):145-52
  • Iurlaro M, Loverro G, Vacca A, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest 1999;29(9):793-801
  • Inoue Y, Abe K, Obata K, et al. Immunohistochemical studies on matrix metalloproteinase-9 (MMP-9) and type-IV collagen in endometrial carcinoma. J Obstet Gynaecol Res 1997;23(2):139-45
  • Graesslin O, Cortez A, Uzan C, et al. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer 2006;16(5):1911-7
  • Karahan N, Guney M, Baspinar S, et al. Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J Gynaecol Oncol 2007;28(3):184-8
  • Aglund K, Rauvala M, Puistola U, et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol 2004;94(3):699-704
  • Lopata A, Agresta F, Quinn MA, et al. Detection of endometrial cancer by determination of matrix metalloproteinases in the uterine cavity. Gynecol Oncol 2003;90(2):318-24
  • Mutter GL, Boynton KA, Faquin WC, et al. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res 1996;56(19):4483-6
  • Moser PL, Hefler L, Tempfer C, et al. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer. Anticancer Res 1999;19(3B):2365-7
  • Honkavuori M, Talvensaari-Mattila A, Soini Y, et al. MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma. Gynecol Oncol 2007;104(1):217-21
  • Yang X, Dong Y, Zhao J, et al. Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract 2007;203(7):499-505
  • Ueno H, Yamashita K, Azumano I, et al. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer 1999;84(5):470-7
  • Misugi F, Sumi T, Okamoto E, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis. Int J Mol Med 2005;16(4):541-6
  • Matrisian LM. Matrix metalloproteinase gene expression. Ann NY Acad Sci 1994;732:42-50
  • Shaco-Levy R, Sharabi S, Piura B, et al. MMP-2, TIMP-1, E-cadherin, and β-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium. Acta Obstet Gynecol Scand 2008;87(8):868-74
  • Honkavuori M, Talvensaari-Mattila A, Puistola U, et al. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Anticancer Res 2008;28(5A):2715-9
  • Inagaki N, Ung L, Otani T, et al. Uterine cavity matrix metalloproteinases and cytokines in patients with leiomyoma, adenomyosis or endometrial polyp. Eur J Obstet Gynecol Reprod Biol 2003;111(2):197-203
  • Erdemoglu E, Guney M, Karahan N, et al. Expression of cyclooxygenase-2, matrix metalloproteinase-2 and matrix metalloproteinase-9 in premenopausal and postmenopausal endometrial polyps. Maturitas 2008;59(3):268-74
  • Isaka K, Nishi H, Nakai H, et al. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer 2003;97(1):79-89
  • Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 2000;60(17):4745-51
  • Stracke JO, Hutton M, Stewart M, et al. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem 2000;275(20):14809-16
  • Zhang J, Cao YJ, Zhao YG, et al. Expression of matrix metalloproteinase-26 and tissue inhibitor of metalloproteinase-4 in human normal cytotrophoblast cells and a choriocarcinoma cell line, JEG-3. Mol Hum Reprod 2002;8(7):659-66
  • Tamakoshi K, Kikkawa F, Nawa A, et al. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer 1995;76(12):2565-71
  • Zhang J, Salamonsen LA. Tissue inhibitor of metalloproteinases (TIMP)-1, -2 and -3 in human endometrium during the menstrual cycle. Mol Hum Reprod 1997;3(9):735-41
  • Kleiner DE Jr, Tuuttila A, Tryggvason K, et al. Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry 1993;32(6):1583-92
  • Zhang J, Hampton AL, Nie G, et al. Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: enzymes coordinately expressed in human endometrium. Biol Reprod 2000;62(1):85-94
  • De Nictolis M, Garbisa S, Lucarini G, et al. 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study. Int J Gynecol Pathol 1996;15(2):102-9
  • Garzetti GG, Ciavattini A, Lucarini G, et al. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125. Anticancer Res 1996;16(4A):2123-7
  • Rauvala M, Puistola U, Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 2005;99(3):656-63
  • Rauvala M, Turpeenniemi-Hujanen T, Puistola U. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer. Anticancer Res 2006;26(6C):4779-84
  • Adamiak A, Postawski K, Semczuk A, et al. Prognostic value of serum MMP-2 level in uterine cancer affected women. Ginekol Pol 2000;71(9):1198-201
  • Bazzett LB, Magnus M, Taylor DD, et al. Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies. Gynecol Oncol 2003;90(2):435-42
  • Sier CF, Casetta G, Verheijen JH, et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res 2000;6(6):2333-40
  • Gerhards S, Jung K, Koenig F, et al. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 2001;57(4):675-9
  • Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 1997;15(3):175-85
  • Brown PD. Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 1995;35:293-301
  • Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69(3):562-73
  • Betz M, Huxley P, Davies SJ, et al. 1.8-Å crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur J Biochem 1997;247(1):356-63
  • Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93(3):178-93
  • Chu QS, Forouzesh B, Syed S, et al. A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 2007;25(4):359-67
  • Steward WP. Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol 1999;43(Suppl):S56-60
  • Yamamoto A, Yano S, Shiraga M, et al. A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Int J Cancer 2003;103(6):822-8
  • Rothenberg ML, Nelson AR, Hande KR. New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells 1999;17(4):237-40
  • Brown PD. Clinical studies with matrix metalloproteinase inhibitors. APMIS 1999;107(1):174-80
  • Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18(5):1135-49
  • Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 1999;878:236-70
  • Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999;43(Suppl):S61-8
  • Rudek MA, Figg WD, Dyer V, et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001;19(2):584-92
  • Davies B, Brown PD, East N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993;53(9):2087-91
  • Giavazzi R, Garofalo A, Ferri C, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998;4(4):985-92
  • Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998;4(8):1899-902
  • Burke F, East N, Upton C, et al. Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. Eur J Cancer 1997;33(7):1114-21
  • Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63(17):5224-9
  • Koop S, Khokha R, Schmidt EE, et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 1994;54(17):4791-7
  • Khokha R, Zimmer MJ, Wilson SM, et al. Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clin Exp Metastasis 1992;10(6):365-70
  • Erba E, Ronzoni S, Bassano L, et al. The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells. Ann Oncol 1999;10(5):589-91
  • Primrose JN, Bleiberg H, Daniel F, et al. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer 1999;79(3-4):509-14
  • Rosemurgy A, Harris J, Langleben A, et al. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 1999;22(3):247-52
  • Nemunaitis J, Poole C, Primrose J, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998;4(5):1101-9
  • Gore M, A'Hern R, Stankiewicz M, et al. Tumour marker levels during marimastat therapy. Lancet 1996;348(9022):263-4
  • Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15(1):61-75
  • Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19(56):6642-50
  • Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008;75(2):346-59

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.